A detailed history of Black Rock Inc. transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Black Rock Inc. holds 1,839,055 shares of ENTA stock, worth $22.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,839,055
Previous 1,934,711 4.94%
Holding current value
$22.5 Million
Previous $18.2 Million 76.37%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$10.08 - $17.46 $964,212 - $1.67 Million
-95,656 Reduced 4.94%
1,839,055 $32.1 Million
Q4 2023

Feb 13, 2024

SELL
$8.18 - $10.78 $362,774 - $478,082
-44,349 Reduced 2.24%
1,934,711 $18.2 Million
Q3 2023

Nov 13, 2023

SELL
$11.09 - $22.13 $19.4 Million - $38.8 Million
-1,751,638 Reduced 46.95%
1,979,060 $22.1 Million
Q2 2023

Aug 11, 2023

SELL
$20.68 - $39.85 $945,158 - $1.82 Million
-45,704 Reduced 1.21%
3,730,698 $79.8 Million
Q1 2023

May 12, 2023

BUY
$38.82 - $54.59 $864,831 - $1.22 Million
22,278 Added 0.59%
3,776,402 $153 Million
Q4 2022

Feb 13, 2023

BUY
$40.77 - $53.73 $5.4 Million - $7.11 Million
132,329 Added 3.65%
3,754,124 $175 Million
Q3 2022

Nov 14, 2022

BUY
$48.29 - $71.27 $4.98 Million - $7.35 Million
103,059 Added 2.93%
3,621,795 $188 Million
Q2 2022

Aug 12, 2022

BUY
$38.13 - $76.93 $81,216 - $163,860
2,130 Added 0.06%
3,518,736 $166 Million
Q1 2022

May 12, 2022

BUY
$56.06 - $74.11 $2.53 Million - $3.35 Million
45,191 Added 1.3%
3,516,606 $250 Million
Q4 2021

Feb 10, 2022

SELL
$60.19 - $97.37 $7.44 Million - $12 Million
-123,638 Reduced 3.44%
3,471,415 $260 Million
Q3 2021

Nov 09, 2021

SELL
$41.02 - $58.65 $3.16 Million - $4.51 Million
-76,953 Reduced 2.1%
3,595,053 $204 Million
Q2 2021

Aug 11, 2021

BUY
$43.76 - $53.11 $161 Million - $195 Million
3,672,006 New
3,672,006 $162 Million

Others Institutions Holding ENTA

About ENANTA PHARMACEUTICALS INC


  • Ticker ENTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,724,900
  • Market Cap $254M
  • Description
  • Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...
More about ENTA
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.